{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.7","value":"1.7"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"4.2","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"209"}],"units":"Participants"}],"description":"Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of \"Not Evaluable (NE).\"","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"OG000","title":"Nivolumab Arm"},{"description":"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends\n\nOR\n\nPaclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"OG001","title":"Active Comparator Arm （Docetaxel/Paclitaxel）"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"(\"Earlier date on which either the overall response was assessed as PD or the subject died of any cause\" - \"Date of randomization\" + 1) / 30.4375.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}